Light-triggered switching of liposome surface charge directs delivery of membrane impermeable payloads in vivo

Arias-Alpizar, Gabriela; Kong, Li; Vlieg, Redmar C.; Rabe, Alexander; Papadopoulou, Panagiota; Meijer, Michael S.; Bonnet, Sylvestre; Vogel, Stefan; Noort, John van; Kros, Alexander; Campbell, Frederick

doi:10.1038/s41467-020-17360-9

Cited by 68 publications

(46 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, the nanoscale size of nanoparticles (NPs) enhances cellular uptake and can optimize intracellular pathways due to their intrinsic physicochemical properties, and can therefore increase drug delivery to target tissues. 47 , 48 However, the inherent targeting ability resulting from the physicochemical properties of NPs is not enough to target specific tissues or damaged tissues, and additional studies on additional ligands that can bind to surface receptors on target cells or tissues have been performed to improve the targeting ability of NPs. 49 Likewise, nanoencapsulation with cell membranes with targeting molecules and encapsulation of the core NPs with cell membranes confer the targeting ability of the source cell to the NPs.…”

Section: Introductionmentioning

confidence: 99%

Stem Cell Mimicking Nanoencapsulation for Targeting Arthritis

Shin¹,

Park²,

Lee³

et al. 2021

IJN

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are considered a promising regenerative therapy due to their ability to migrate toward damaged tissues. The homing ability of MSCs is unique compared with that of non-migrating cells and MSCs are considered promising therapeutic vectors for targeting major cells in many pathophysiological sites. MSCs have many advantages in the treatment of malignant diseases, particularly rheumatoid arthritis (RA). RA is a representative autoimmune disease that primarily affects joints, and secreted chemokines in the joints are well recognized by MSCs following their migration to the joints. Furthermore, MSCs can regulate the inflammatory process and repair damaged cells in the joints. However, the functionality and migration ability of MSCs injected in vivo still show insufficient. The targeting ability and migration efficiency of MSCs can be enhanced by genetic engineering or modification, eg, overexpressing chemokine receptors or migration-related genes, thus maximizing their therapeutic effect. However, there are concerns about genetic changes due to the increased probability of oncogenesis resulting from genome integration of the viral vector, and thus, clinical application is limited. Furthermore, it is suspected that administering MSCs can promote tumor growth and metastasis in xenograft and orthotopic models. For this reason, MSC mimicking nanoencapsulations are an alternative strategy that does not involve using MSCs or bioengineered MSCs. MSC mimicking nanoencapsulations consist of MSC membrane-coated nanoparticles, MSC-derived exosomes and artificial ectosomes, and MSC membrane-fused liposomes with natural or genetically engineered MSC membranes. MSC mimicking nanoencapsulations not only retain the targeting ability of MSCs but also have many advantages in terms of targeted drug delivery. Specifically, MSC mimicking nanoencapsulations are capable of encapsulating drugs with various components, including chemotherapeutic agents, nucleic acids, and proteins. Furthermore, there are fewer concerns over safety issues on MSC mimicking nanoencapsulations associated with mutagenesis even when using genetically engineered MSCs, because MSC mimicking nanoencapsulations use only the membrane fraction of MSCs. Genetic engineering is a promising route in clinical settings, where nano-encapsulated technology strategies are combined. In this review, the mechanism underlying MSC homing and the advantages of MSC mimicking nanoencapsulations are discussed. In addition, genetic engineering of MSCs and MSC mimicking nanoencapsulation is described as a promising strategy for the treatment of immune-related diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Stem Cell Mimicking Nanoencapsulation for Targeting Arthritis

Shin¹,

Park²,

Lee³

et al. 2021

IJN

View full text Add to dashboard Cite

show abstract

“…It needs to be emphasized here that the correlation of in vivo behaviors in zebrafish and mice is qualitative. [12,38] First, the differences in blood components, temperature, scale, flow rate, and shearing force in these two models resulted in much faster disassembly kinetics and elimination of polymeric NCs in the mouse model than zebrafish model. However, the disassembly rate, circulation time, and elimination rate of these three polymeric NCs in the zebrafish model had the same tendency as the mouse model.…”

Section: Discussionmentioning

confidence: 99%

Particle Integrity and Size Effect on the Journey of Polymeric Nanocarriers in Zebrafish Model and the Correlation with Mice

Tao

Wei

et al. 2021

Small

View full text Add to dashboard Cite

block (polyethylene glycol (PEG)) and hydrophobic block (such as polycaprolactone (PCL), poly lactic-co-glycolic acid, and poly-d,l-lactic acid) have promising applications to deliver water-insoluble drugs owing to their stealth shell-hydrophobic core structure. However, to date, only a few polymeric NCs (excluding biologics) were approved in clinics, such as GenexolPM/Cynviloq (Samyang Biopharm), Nanoxel (Fresenius Kabi), and Apealea/Paclical (Oasmia Pharmaceuticals). [2] There exists a large gap from basic research to the clinical transformation of polymeric NCs because they cannot offer a significantly improved therapeutic benefit over the free drug. [3][4][5] Once entering the blood circulation, polymeric NCs will face a complex biological environment (e.g., dilution, shear force, and protein adsorption) and various plasma components, which will dramatically affect their biofate. [4] Polymeric NCs may lose their integrity in blood circulation. Intact polymeric NCs may be recognized and rapidly sequestered by reticuloendothelial system (RES) and further eliminated from the systemic circulation. However, due to the lack of sufficient understanding of their biofate and parameters that could regulate in vivo processes, the behaviors of polymeric NCs in vivo could not be well controlled, resulting in unsatisfactory therapeutic benefit.Moreover, the in vivo characterization and optimization of NCs are also challenging in early formulation development in the absence of a proper screening model. The in vivo fate of polymeric NCs not only depends on the biological environment but also relies on their physicochemical properties, such as particle size, shape, surface modification, and charge, which offer enormous possibilities for formulation optimization. [3,6,7] Although in vitro cell models are conventional drug screening tools, they cannot completely reflect or mimic the in vivo biological environment, resulting in formulations screened in cell models that might not work in rodent models. [8] Moreover, rodent experiments are time-consuming and costly, failing to assess a large number of formulations in a short time. Thus, there exists an urgent demand for a suitable preclinical model Polymeric nanocarriers have high biocompatibility for potential drug delivery applications. After entering bloodstream, nanocarriers will circulate, interact with proteins, dissociate, or be cleared by reticuloendothelial system. Zebrafish as a visual animal model, can serve as a tool for screening nanomedicines and monitoring nanocarrier behaviors in vivo. However, a comprehensive correlation between zebrafish and rodent models is currently deficient. Here, different-sized poly(caprolactone) nanocarriers (PCL NCs) are fabricated with or without PEGylation to investigate correlation between zebrafish and mice regarding their biofate via Förster resonance energy transfer technique. Results show that PEGylated PCL NCs have higher integrity in both zebrafish and mice. Small PEG-PCL NCs have longer circulation, while large PEG-PCL NCs have ...

show abstract

“…Figure S2A), electrostatic repulsion may contribute to the barrier function of HA and possibly also of other glycocalyx components. 24 The charge of the glycocalyx at the interface with the surrounding fluid, where the Stern counterion layer is generated, is the most relevant for target particle engagement. We therefore measured the zeta potential (i.e., the potential difference between the dispersion medium and the Stern layer of both cells and their targets) using electrophoretic light scattering.…”

Section: High-molecular-weight Forms Of Ha In Synovial Fluid Obstructmentioning

confidence: 99%

An Acquired and Endogenous Glycocalyx Forms a Bidirectional “Don’t Eat” and “Don’t Eat Me” Barrier to Phagocytosis

et al. 2021

View full text Add to dashboard Cite

Light-triggered switching of liposome surface charge directs delivery of membrane impermeable payloads in vivo

Cited by 68 publications

References 82 publications

Stem Cell Mimicking Nanoencapsulation for Targeting Arthritis

Stem Cell Mimicking Nanoencapsulation for Targeting Arthritis

Particle Integrity and Size Effect on the Journey of Polymeric Nanocarriers in Zebrafish Model and the Correlation with Mice

An Acquired and Endogenous Glycocalyx Forms a Bidirectional “Don’t Eat” and “Don’t Eat Me” Barrier to Phagocytosis

Contact Info

Product

Resources

About